These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37468110)

  • 1. Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks.
    Aly AE; Caron NS; Black HF; Schmidt ME; Anderson C; Ko S; Baddeley HJE; Anderson L; Casal LL; Rahavi RSM; Martin DDO; Hayden MR
    J Control Release; 2023 Aug; 360():913-927. PubMed ID: 37468110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease.
    Caron NS; Aly AE; Findlay Black H; Martin DDO; Schmidt ME; Ko S; Anderson C; Harvey EM; Casal LL; Anderson LM; Rahavi SMR; Reid GSD; Oda MN; Stanimirovic D; Abulrob A; McBride JL; Leavitt BR; Hayden MR
    J Control Release; 2024 Mar; 367():27-44. PubMed ID: 38215984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice.
    Caron NS; Byrne LM; Lemarié FL; Bone JN; Aly AE; Ko S; Anderson C; Casal LL; Hill AM; Hawellek DJ; McColgan P; Wild EJ; Leavitt BR; Hayden MR
    Transl Neurodegener; 2024 Oct; 13(1):50. PubMed ID: 39380076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic.
    Rook ME; Southwell AL
    BioDrugs; 2022 Mar; 36(2):105-119. PubMed ID: 35254632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
    Monine M; Norris D; Wang Y; Nestorov I
    J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translating Antisense Technology into a Treatment for Huntington's Disease.
    Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
    Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.
    Carroll JB; Warby SC; Southwell AL; Doty CN; Greenlee S; Skotte N; Hung G; Bennett CF; Freier SM; Hayden MR
    Mol Ther; 2011 Dec; 19(12):2178-85. PubMed ID: 21971427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice.
    Caron NS; Banos R; Aly AE; Xie Y; Ko S; Potluri N; Anderson C; Black HF; Anderson LM; Gordon B; Southwell AL; Hayden MR
    Neurobiol Dis; 2022 May; 166():105652. PubMed ID: 35143966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleic Acid Therapeutics in Huntington's Disease.
    Singh K; Roy I
    Recent Pat Biotechnol; 2019; 13(3):187-206. PubMed ID: 30747088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion.
    Keller CG; Shin Y; Monteys AM; Renaud N; Beibel M; Teider N; Peters T; Faller T; St-Cyr S; Knehr J; Roma G; Reyes A; Hild M; Lukashev D; Theil D; Dales N; Cha JH; Borowsky B; Dolmetsch R; Davidson BL; Sivasankaran R
    Nat Commun; 2022 Mar; 13(1):1150. PubMed ID: 35241644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stem cells alleviate AQP-4-dependent glymphatic dysfunction and improve brain distribution of antisense oligonucleotides in BACHD mice.
    Wu TT; Su FJ; Feng YQ; Liu B; Li MY; Liang FY; Li G; Li XJ; Zhang Y; Cai ZQ; Pei Z
    Stem Cells; 2020 Feb; 38(2):218-230. PubMed ID: 31648394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.
    Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A
    Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the therapeutic development for Huntington disease.
    Mestre TA
    Parkinsonism Relat Disord; 2019 Feb; 59():125-130. PubMed ID: 30616867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-Dependent Lowering of Mutant Huntingtin Using Antisense Oligonucleotides in Huntington Disease Patients.
    van Roon-Mom WMC; Roos RAC; de Bot ST
    Nucleic Acid Ther; 2018 Apr; 28(2):59-62. PubMed ID: 29620999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Huntingtin-lowering strategies for Huntington's disease.
    Barker RA; Fujimaki M; Rogers P; Rubinsztein DC
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1125-1132. PubMed ID: 32745442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
    J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease.
    Southwell AL; Kordasiewicz HB; Langbehn D; Skotte NH; Parsons MP; Villanueva EB; Caron NS; Østergaard ME; Anderson LM; Xie Y; Cengio LD; Findlay-Black H; Doty CN; Fitsimmons B; Swayze EE; Seth PP; Raymond LA; Frank Bennett C; Hayden MR
    Sci Transl Med; 2018 Oct; 10(461):. PubMed ID: 30282695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclodextrin-Based Nanoparticles for Delivery of Antisense Oligonucleotides Targeting Huntingtin.
    Mendonça MCP; Sun Y; Cronin MF; Lindsay AJ; Cryan JF; O'Driscoll CM
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease.
    Caron NS; Banos R; Yanick C; Aly AE; Byrne LM; Smith ED; Xie Y; Smith SEP; Potluri N; Findlay Black H; Casal L; Ko S; Cheung D; Kim H; Seong IS; Wild EJ; Song JJ; Hayden MR; Southwell AL
    J Neurosci; 2021 Jan; 41(4):780-796. PubMed ID: 33310753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic strategies for Huntington's disease.
    Estevez-Fraga C; Flower MD; Tabrizi SJ
    Curr Opin Neurol; 2020 Aug; 33(4):508-518. PubMed ID: 32657893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.